Pharmacologic Substance: Anti-Obesity Agents

Medical news and research articles

Biden plan to expand obesity drug coverage is rejected

The Trump administration has decided not to expand Medicare and Medicaid coverage for popular obesity drugs, blocking a Biden administration initiative that could have helped millions of Americans access the medications.

Weighing the high cost of obesity reduction drugs

University of Chicago researchers assessed the long-term health outcomes and cost-effectiveness of four antiobesity medications compared to lifestyle modification alone. Results indicate that tirzepatide and semaglutide provide ...

page 3 from 7